NTLA Intellia Therapeutics, Inc. Stock Quote

NTLA [NASD]

Index	-	P/E	-	EPS (ttm)	-3.36	Insider Own	1.00%	Shs Outstand	73.71M	Perf Week	-10.70%
Market Cap	8.18B	Forward P/E	-	EPS next Y	-3.85	Insider Trans	-58.19%	Shs Float	67.02M	Perf Month	-25.66%
Income	-228.80M	PEG	-	EPS next Q	-1.05	Inst Own	82.40%	Short Float	5.18%	Perf Quarter	-42.85%
Sales	26.80M	P/S	305.31	EPS this Y	-13.80%	Inst Trans	1.02%	Short Ratio	4.65	Perf Half Y	30.09%
Book/sh	15.02	P/B	6.73	EPS next Y	0.60%	ROA	-26.90%	Target Price	174.56	Perf Year	135.39%
Cash/sh	9.86	P/C	10.25	EPS next 5Y	30.00%	ROE	-34.20%	52W Range	39.81 - 202.73	Perf YTD	85.72%
Dividend	-	P/FCF	-	EPS past 5Y	-46.70%	ROI	-	52W High	-50.17%	Beta	2.07
Dividend %	-	Quick Ratio	8.40	Sales past 5Y	57.20%	Gross Margin	-	52W Low	153.78%	ATR	7.16
Employees	312	Current Ratio	8.40	Sales Q/Q	-67.60%	Oper. Margin	-	RSI (14)	28.33	Volatility	8.32% 6.02%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-105.10%	Profit Margin	-	Rel Volume	1.26	Prev Close	109.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 BMO	Payout	-	Avg Volume	745.92K	Price	101.03
Recom	2.10	SMA20	-19.70%	SMA50	-22.61%	SMA200	-8.56%	Volume	938,827	Change	-8.11%

Oct-05-21

Initiated

Guggenheim

Buy

$170

Sep-24-21

Initiated

Stifel

Buy

$173

Jun-28-21

Reiterated

H.C. Wainwright

Buy

$111 → $171

Jun-11-21

Initiated

H.C. Wainwright

Buy

$111

May-07-21

Upgrade

ROTH Capital

Neutral → Buy

$75 → $80

May-04-21

Initiated

RBC Capital Mkts

Outperform

$110

Mar-04-21

Initiated

JMP Securities

Mkt Outperform

$80

Dec-22-20

Downgrade

Robert W. Baird

Outperform → Neutral

$60

Oct-27-20

Initiated

Truist

Buy

$40

Oct-14-20

Initiated

Wells Fargo

Overweight

Sep-18-20

Initiated

Goldman

Buy

$33

Feb-28-20

Upgrade

Oppenheimer

Perform → Outperform

Feb-14-20

Downgrade

Wedbush

Outperform → Neutral

$16

Nov-01-19

Upgrade

Raymond James

Mkt Perform → Outperform

Jul-09-19

Initiated

Robert W. Baird

Outperform

$23

Jun-10-19

Initiated

ROTH Capital

Neutral

$16

May-03-19

Upgrade

Wedbush

Neutral → Outperform

$20 → $21

Apr-12-19

Initiated

Evercore ISI

Outperform

Nov-02-18

Downgrade

Wedbush

Outperform → Neutral

$36 → $20

Oct-29-18

Initiated

Credit Suisse

Neutral

$24

Nov-22-21 07:30AM	Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) GlobeNewswire
Nov-21-21 11:31AM	Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? Motley Fool
Nov-12-21 09:34AM	Intellia Therapeutics (NASDAQ:NTLA) shareholders have earned a 51% CAGR over the last five years Simply Wall St.
Nov-10-21 11:43AM	Notable Intellia Therapeutics Insider Trades $350K In Company Stock Benzinga -8.37%
10:48AM	Were These Hedge Funds Right About Piling Into Intellia Therapeutics, Inc. (NTLA)? Insider Monkey
Nov-06-21 12:30PM	Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript Motley Fool
Nov-05-21 07:30AM	Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-04-21 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM	Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? Zacks
Oct-28-21 03:26PM	10 Growth Stocks to Buy According to Jay Chens Himension Capital Insider Monkey +5.02%
03:05PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates GlobeNewswire
Oct-22-21 10:22AM	Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag Zacks
Oct-21-21 07:30AM	Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis GlobeNewswire
Oct-20-21 07:30AM	Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress GlobeNewswire
Oct-19-21 09:25AM	11 Best Genomic Stocks to Buy Now Insider Monkey
Oct-15-21 09:57AM	Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week Motley Fool
Oct-13-21 07:01AM	Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology GlobeNewswire
Oct-12-21 07:01PM	Cathie Woods ARK Funds Snapped Up Crispr Shares Ahead of Plunge Bloomberg
11:58AM	Hedge Funds Are Crazy About Intellia Therapeutics, Inc. (NTLA) Insider Monkey
07:30AM	Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress GlobeNewswire
Oct-06-21 08:29AM	Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients Benzinga
07:30AM	Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema GlobeNewswire
Sep-27-21 11:58AM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Could Be 20% Below Their Intrinsic Value Estimate Simply Wall St.
07:30AM	Intellia Therapeutics to Present at Chardans 5th Annual Genetic Medicines Conference GlobeNewswire
Sep-17-21 01:35PM	Is Intellia Therapeutics (NTLA) A Great Investment Pick? Insider Monkey
Sep-16-21 10:10AM	Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients Benzinga
07:30AM	Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia GlobeNewswire
Aug-31-21 07:30AM	Intellia Therapeutics to Present at September Healthcare Investor Conferences GlobeNewswire
Aug-26-21 12:45PM	12 Best ARK Stocks To Invest In Insider Monkey
Aug-24-21 10:56AM	New Strong Sell Stocks for August 24th Zacks
Aug-17-21 10:21AM	Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why Zacks
Aug-14-21 08:00AM	How Are Genomics ETFs Responding to Q2 Earnings? Zacks
Aug-12-21 08:31AM	Let's Get Some Trading Intelligence on Intellia Therapeutics TheStreet.com
Aug-06-21 08:01PM	Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 03:59PM	Why Shares of Intellia Therapeutics Are Jumping Today Motley Fool +12.40%
09:01AM	Intellia Stock Jumps on Progress With Gene-Editing Treatment TheStreet.com
08:45AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:30AM	Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress GlobeNewswire
Aug-02-21 08:52AM	Intellia (NTLA) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-29-21 03:05PM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates GlobeNewswire
Jul-27-21 05:50PM	Intellia Therapeutics, Inc. (NTLA) Dips More Than Broader Markets: What You Should Know Zacks
Jul-16-21 11:02AM	Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week Motley Fool
05:32AM	What Type Of Shareholders Make Up Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Share Registry? Simply Wall St.
Jul-15-21 08:19AM	After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding Motley Fool
Jul-12-21 03:12PM	WHO Issues Framework For Governance For Gene Editing Technologies Benzinga
Jul-11-21 07:01AM	Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results Motley Fool
Jul-10-21 05:19AM	Is It Too Late to Buy Intellia Therapeutics? Motley Fool
Jul-09-21 04:04PM	A Comprehensive Guide to Genomic ETFs Zacks
Jul-06-21 11:28AM	Hedge Funds Are Cashing Out Of Intellia Therapeutics, Inc. (NTLA) Insider Monkey -8.71%
Jul-04-21 07:49AM	2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't Motley Fool
Jul-02-21 04:35PM	Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus Investor's Business Daily
04:01PM	Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock GlobeNewswire
12:48PM	Here's What Drove Gene Editing Stocks Higher This Week Motley Fool
Jul-01-21 06:56AM	5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now Motley Fool +6.02%
Jun-30-21 10:14PM	German Launch Startup Pitches Taxi to Space: Catalyst Update Bloomberg +6.79%
04:20PM	Why Intellia Therapeutics Was a Winner on Wednesday Motley Fool
04:04PM	Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More Zacks
03:30PM	In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC Benzinga
01:14PM	Genomics ETFs Surge on a Major Breakthrough in CRISPR Study Zacks
12:14PM	Intellia Therapeutics Leads Gene-Editing Stock Rally TheStreet.com
11:32AM	Here Are the Best and Worst Biopharma Stock Performers So Far This Year Barrons.com
08:46AM	Implied Volatility Surging for Intellia Therapeutics (NTLA) Stock Options Zacks
06:47AM	Can Intellia Therapeutics Turn Exciting Trial Results into Profits? Motley Fool
06:42AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals Zacks
Jun-29-21 09:08PM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire +13.63%
11:20AM	Intellia (NTLA) Up on Positive Gene-Editing Drug Interim Data Zacks
09:55AM	3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data Zacks
09:34AM	Company News for Jun 29, 2021 Zacks
06:58AM	Intellia Seeks To Raise $400M Via Equity Benzinga
05:15AM	Intellia Therapeutics Busts Out of Resistance on Positive Trial News TheStreet.com
Jun-28-21 04:25PM	Cathie Wood Funds Jump as Gene Editing Edges Closer to Reality Bloomberg +50.21%
04:12PM	Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR Investor's Business Daily
04:01PM	Intellia Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
02:36PM	Nasdaq surges to record, FAA stalls Boeing 777X, airline stocks nosedive, AMC & GameStop jump Yahoo Finance Video
01:17PM	Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money Motley Fool
12:22PM	Why Beam Therapeutics Jumped Today Motley Fool
12:17PM	Why Editas Medicine Stock Is Jumping Today Motley Fool
11:09AM	Why Intellia Therapeutics Stock Is Skyrocketing Today Motley Fool
10:39AM	Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough Barrons.com
10:02AM	Dow Jones Lags, Nasdaq Leads In Mixed Open; Biotechs Rocket On Intellia CRISPR News; Salesforce.com Stock Climbs Investor's Business Daily
10:00AM	Baird suspends GameStop, Virgin Galactic and Intellia Therapeutics soar Yahoo Finance Video
09:15AM	Trading Intellia Therapeutics, ARKG ETF After Breakthrough Data TheStreet.com
08:41AM	5 Top Stock Gainers for Monday: Intellia Therapeutics, QAD, Etsy, Nvidia TheStreet.com
08:39AM	Gene Editing Data Look Good for Intellia. How It Made History. Barrons.com
06:09AM	Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate Benzinga
05:34AM	Intellia Soars On Positive Results In Gene-Editing Treatment Investing.com
04:52AM	Premarket Movers Monday: Intellia Therapeutics, Boeing, Nvidia TheStreet.com
04:06AM	Boeing, Tesla and Johnson & Johnson Fall Premarket Investing.com
03:19AM	Intellia Therapeutics Soars on Trial Results Using Crispr Technology TheStreet.com
Jun-27-21 07:25AM	Intellia Stock Could Surge 35-45% After Positive Gene Editing Data, Says Analyst TipRanks
Jun-26-21 08:00PM	Crispr gene-editing revolution treats internal organ for first time Financial Times
01:07PM	Gene Editing Data Look Good for Intellia. How It Made History. Barrons.com
11:16AM	Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis PR Newswire
Jun-25-21 04:45AM	This Biotech Is Editing Genes Inside the Body. What It Means for the Stock. Barrons.com
Jun-24-21 07:30AM	Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary GlobeNewswire
Jun-22-21 07:00AM	Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company Business Wire
06:41AM	3 Biotech Stocks With Big Catalysts in June Motley Fool

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lebwohl David	EVP, Chief Medical Officer	Nov 05	Option Exercise	12.62	2,400	30,288	11,114	Nov 09 06:08 PM
Lebwohl David	EVP, Chief Medical Officer	Nov 05	Sale	132.72	2,400	318,535	8,714	Nov 09 06:08 PM
Lebwohl David	EVP, Chief Medical Officer	Oct 14	Option Exercise	12.62	2,400	30,288	11,114	Oct 15 07:02 PM
Lebwohl David	EVP, Chief Medical Officer	Oct 14	Sale	128.44	2,400	308,249	8,714	Oct 15 07:02 PM
Crowley John F	Director	Oct 11	Option Exercise	18.83	2,500	47,075	4,594	Oct 13 04:15 PM
Crowley John F	Director	Oct 11	Sale	119.55	2,500	298,875	2,094	Oct 13 04:15 PM
Crowley John F	Director	Oct 05	Option Exercise	18.83	10,000	188,300	12,094	Oct 07 05:41 PM
Crowley John F	Director	Oct 05	Sale	130.54	10,000	1,305,391	2,094	Oct 07 05:41 PM
Lebwohl David	EVP, Chief Medical Officer	Sep 24	Option Exercise	12.62	7,923	99,988	8,714	Sep 27 04:15 PM
Lebwohl David	EVP, Chief Medical Officer	Sep 21	Option Exercise	12.62	2,400	30,288	3,191	Sep 23 05:48 PM
Lebwohl David	EVP, Chief Medical Officer	Sep 21	Sale	149.81	2,400	359,544	791	Sep 23 05:48 PM
Goddard Glenn	EVP, Chief Financial Officer	Sep 07	Option Exercise	14.58	3,482	50,768	3,482	Sep 09 05:38 PM
Goddard Glenn	EVP, Chief Financial Officer	Sep 07	Sale	180.12	3,482	627,178	0	Sep 09 05:38 PM
LEONARD JOHN M	President and CEO	Sep 01	Option Exercise	21.62	44,735	967,000	764,040	Sep 01 08:21 PM
LEONARD JOHN M	President and CEO	Sep 01	Sale	170.00	44,735	7,604,950	719,305	Sep 01 08:21 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 31	Option Exercise	18.93	24,800	469,374	24,800	Sep 01 07:30 PM
LEONARD JOHN M	President and CEO	Aug 31	Option Exercise	14.58	37,833	551,605	757,138	Sep 01 08:21 PM
LEONARD JOHN M	President and CEO	Aug 31	Sale	155.00	37,833	5,864,115	719,305	Sep 01 08:21 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 31	Sale	160.22	24,800	3,973,456	0	Sep 01 07:30 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 30	Option Exercise	19.27	5,200	100,204	5,200	Sep 01 07:30 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 30	Option Exercise	12.62	2,400	30,288	3,191	Sep 01 07:32 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 30	Option Exercise	14.01	97,000	1,359,300	99,391	Sep 01 07:34 PM
LEONARD JOHN M	President and CEO	Aug 30	Option Exercise	14.23	38,804	552,031	758,109	Sep 01 08:21 PM
LEONARD JOHN M	President and CEO	Aug 30	Sale	155.95	38,804	6,051,353	719,305	Sep 01 08:21 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 30	Sale	154.83	97,000	15,018,054	2,391	Sep 01 07:34 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 30	Sale	158.04	2,400	379,300	791	Sep 01 07:32 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 30	Sale	155.78	5,200	810,082	0	Sep 01 07:30 PM
LEONARD JOHN M	President and CEO	Aug 23	Option Exercise	13.40	27,139	363,663	746,444	Aug 25 04:14 PM
LEONARD JOHN M	President and CEO	Aug 23	Sale	152.01	27,139	4,125,416	719,305	Aug 25 04:14 PM
LEONARD JOHN M	President and CEO	Aug 19	Option Exercise	13.40	22,682	303,939	741,987	Aug 20 06:14 PM
LEONARD JOHN M	President and CEO	Aug 19	Sale	151.28	22,682	3,431,398	719,305	Aug 20 06:14 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 09	Option Exercise	12.62	2,400	30,288	3,191	Aug 11 04:50 PM
Lebwohl David	EVP, Chief Medical Officer	Aug 09	Sale	164.05	2,400	393,720	791	Aug 11 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 05	Option Exercise	19.27	20,000	385,400	20,000	Aug 06 06:17 PM
Goddard Glenn	EVP, Chief Financial Officer	Aug 05	Sale	151.05	20,000	3,021,056	0	Aug 06 06:17 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 04	Option Exercise	13.40	26,000	348,400	28,391	Aug 06 06:19 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Aug 04	Sale	138.24	26,000	3,594,357	2,391	Aug 06 06:19 PM
FORMELA JEAN FRANCOIS	Director	Jun 28	Sale	132.73	553,376	73,448,879	10,000	Jun 29 09:48 AM
FORMELA JEAN FRANCOIS	Director	Jun 14	Sale	87.37	170,779	14,921,294	563,376	Jun 15 09:51 AM
FORMELA JEAN FRANCOIS	Director	Jun 11	Sale	85.23	30,946	2,637,480	734,155	Jun 15 09:51 AM
FORMELA JEAN FRANCOIS	Director	Apr 29	Sale	85.43	4,513	385,546	765,101	Apr 30 08:55 PM
FORMELA JEAN FRANCOIS	Director	Apr 28	Sale	85.56	131,926	11,287,893	769,614	Apr 28 07:51 PM
FORMELA JEAN FRANCOIS	Director	Apr 27	Sale	86.22	210,230	18,125,992	901,540	Apr 28 07:51 PM
FORMELA JEAN FRANCOIS	Director	Apr 26	Sale	84.93	806	68,454	1,111,770	Apr 28 07:51 PM
LEONARD JOHN M	President and CEO	Apr 13	Option Exercise	11.16	25,937	289,506	719,305	Apr 15 08:50 PM
DORSA CAROLINE	Director	Apr 05	Option Exercise	6.40	7,500	48,000	12,910	Apr 06 06:09 PM
FORMELA JEAN FRANCOIS	Director	Apr 05	Sale	84.98	800	67,984	1,112,576	Apr 07 02:14 PM
DORSA CAROLINE	Director	Apr 05	Sale	82.19	7,500	616,405	5,410	Apr 06 06:09 PM
Rivera Jose E	EVP, General Counsel	Apr 01	Option Exercise	12.51	97,001	1,213,537	178,077	Apr 02 08:42 PM
LEONARD JOHN M	President and CEO	Apr 01	Option Exercise	14.15	71,041	1,005,049	707,263	Apr 02 08:46 PM
LEONARD JOHN M	President and CEO	Apr 01	Sale	83.64	38,209	3,195,661	681,222	Apr 02 08:46 PM
Rivera Jose E	EVP, General Counsel	Apr 01	Sale	82.46	50,455	4,160,559	131,032	Apr 02 08:42 PM
FORMELA JEAN FRANCOIS	Director	Feb 26	Sale	60.29	501,945	30,262,716	1,113,376	Mar 01 01:59 PM
LEONARD JOHN M	President and CEO	Feb 09	Option Exercise	6.83	56,718	387,384	688,579	Feb 09 08:36 PM
Rivera Jose E	EVP, General Counsel	Feb 09	Option Exercise	18.30	21,000	384,195	129,409	Feb 09 08:38 PM
Rivera Jose E	EVP, General Counsel	Feb 09	Sale	75.00	11,489	861,675	117,920	Feb 09 08:38 PM
LEONARD JOHN M	President and CEO	Feb 09	Sale	75.00	28,043	2,103,225	660,536	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 05	Option Exercise	13.40	40,000	536,000	654,803	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 05	Sale	67.66	22,942	1,552,185	631,861	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 03	Option Exercise	17.68	117,060	2,069,793	651,661	Feb 03 09:39 PM
LEONARD JOHN M	President and CEO	Feb 03	Sale	72.54	67,856	4,922,490	584,601	Feb 03 09:39 PM
Rivera Jose E	EVP, General Counsel	Feb 01	Option Exercise	9.68	109,000	1,054,620	121,686	Feb 03 09:38 PM
LEONARD JOHN M	President and CEO	Feb 01	Option Exercise	13.69	200,000	2,737,600	598,814	Feb 03 09:39 PM
LEONARD JOHN M	President and CEO	Feb 01	Sale	64.00	109,889	7,032,905	523,853	Feb 03 09:39 PM
Rivera Jose E	EVP, General Counsel	Feb 01	Sale	63.99	54,659	3,497,902	88,686	Feb 03 09:38 PM
Cohen Fred E	Director	Jan 20	Option Exercise	13.78	20,000	275,600	30,000	Jan 22 04:22 PM
LEONARD JOHN M	President and CEO	Jan 05	Sale	55.86	6,239	348,511	475,488	Jan 05 09:24 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Jan 05	Sale	55.86	1,377	76,919	16,656	Jan 05 08:58 PM
Rivera Jose E	EVP, General Counsel	Jan 05	Sale	55.86	2,078	116,077	51,990	Jan 05 08:55 PM
LEONARD JOHN M	President and CEO	Dec 31	Option Exercise	0.00	14,375	0	481,727	Jan 05 09:24 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Dec 31	Option Exercise	0.00	4,792	0	18,033	Jan 05 08:58 PM
Rivera Jose E	EVP, General Counsel	Dec 31	Option Exercise	0.00	4,792	0	54,068	Jan 05 08:55 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Dec 30	Option Exercise	13.48	1,500	20,220	12,673	Jan 04 09:03 PM
KARSEN PERRY A	Director	Dec 17	Option Exercise	18.45	88,764	1,637,842	93,764	Dec 18 04:29 PM
KARSEN PERRY A	Director	Dec 17	Sale	53.55	88,764	4,753,680	5,000	Dec 18 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience